Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation
JD Supra Law
DECEMBER 13, 2023
Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA®. By: Goodwin
Let's personalize your content